Compare CarMax, Inc (KMX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Viatris Inc — how do they compare? CarMax, Inc trades at $58.09 (market cap $8.26B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 2.3× CarMax, Inc's market cap, and Viatris Inc pays a 2.95% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.
| KMX | VTRS | |
|---|---|---|
Market Cap | $8.26B | $18.69B |
Sector | Consumer Cyclical | Health |
52-Week High | $62.17 | $17.86 |
52-Week Low | $30.88 | $9.49 |
Enterprise Value | $26.77B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $58.78, up 1.03% today, with a bullish technical signal and strong analyst support. Recent earnings have beaten expectations, with Q3 2025 and Q1 2026 EPS surpassing estimates, though Q2 2025 missed. Revenue remains stable around $26.4 billion, but net income margin is thin at 0.84%. The stock is near its consensus price target of $53.09, with a high target of $66.00. Positive news includes a Zacks Strong Buy rating and partnerships to enhance customer experience.
The outlook for KMX is cautiously optimistic, driven by earnings beats and bullish technicals, but high debt and margin pressures pose risks. Investment opportunity lies in continued execution and market share gains, while risks include competitive pressures and economic sensitivity. Analyst consensus leans Hold, with 68.58% holding, suggesting a wait-and-see approach for further growth confirmation.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
